Detalhe da pesquisa
1.
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
J Clin Invest
; 117(9): 2638-48, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17786246
2.
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Cancer Discov
; 10(8): 1174-1193, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32404308
3.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Cancer Discov
; 9(2): 248-263, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30373917
4.
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.
Mol Cancer Ther
; 13(2): 364-74, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24356814
5.
Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.
Mol Cancer Ther
; 9(12): 3158-63, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20971826
6.
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.
Cancer Res
; 69(9): 3866-73, 2009 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19383915
7.
Discovery of non-covalent dipeptidyl peptidase IV inhibitors which induce a conformational change in the active site.
Bioorg Med Chem Lett
; 17(6): 1765-8, 2007 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17239592